AbbVie cuts away part of its partnership with Morphic on integrin research for fibrosis

Kyle Blankenship

Despite a quiet few years, Morphic Therapeutic was once a buzzy biotech looking to move integrin research into the next generation. Now, a drug giant partner is quietly ditching part of its collaboration with the biotech.

AbbVie has decided to discontinue research into the αVβ6 integrin as part of a deal with Morphic dating back to 2018, the biotech said Thursday.

Snuck quietly into an earnings release, Morphic said AbbVie opted to walk on that part of the collaboration but didn’t offer any specific reason why. The company noted that research into other integrin targets is still ongoing despite the setback.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

AbbVie cuts away part of its partnership with Morphic on integrin research for fibrosis

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Ab­b­Vie cuts away part of its part­ner­ship with Mor­phic on in­te­grin re­search for fi­bro­sis

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

AbbVie cuts away part of its partnership with Morphic on integrin research for fibrosis

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir